- 中文名稱
ADORA2A 一抗
- 英文名字
- ADORA2A Primary antibody
- 供應(yīng)商
- Promab
- 產(chǎn)品貨號
- PMB-31299
- 產(chǎn)品報(bào)價(jià)
- ¥詢價(jià)/100ul

- 產(chǎn)品說明書
- 點(diǎn)擊查看
- 購買方式
- Promab中國區(qū)現(xiàn)貨中心已經(jīng)建立,95%產(chǎn)品中國有現(xiàn)貨庫存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金,在線支付寶及網(wǎng)銀支付,或直接與我們電話聯(lián)系。本公司所有產(chǎn)品僅供科研使用,不用于臨床診斷。
- 產(chǎn)品新聞

- 背景資料
- This gene encodes a member of the guanine nucleotide-binding protein (G protein)-coupled receptor (GPCR) superfamily, which is subdivided into classes and subtypes. The receptors are seven-pass transmembrane proteins that respond to extracellular cues and activate intracellular signal transduction pathways. This protein, an adenosine receptor of A2A subtype, uses adenosine as the preferred endogenous agonist and preferentially interacts with the G(s) and G(olf) family of G proteins to increase intracellular cAMP levels. It plays an important role in many biological functions, such as cardiac rhythm and circulation, cerebral and renal blood flow, immune function, pain regulation, and sleep. It has been implicated in pathophysiological conditions such as inflammatory diseases and neurodegenerative disorders. Alternative splicing results in multiple transcript variants. A read-through transcript composed of the upstream SPECC1L (sperm antigen with calponin homology and coiled-coil domains 1-like) and ADORA2A (adenosine A2a receptor) gene sequence has been identified, but it is thought to be non-coding.
- 應(yīng)用類型
- ICC,FCM
- 免疫原
- Purified recombinant fragment of human ADORA2A (AA: 274-412) expressed in E. Coli.
- 來源宿主
- Mouse
- 反應(yīng)性
- Human
- 保存建議
- 4℃短期保存;-20℃長期保存。避免凍融循環(huán)。
- 其他
- ProMab 生物技術(shù)公司通過整合生物信息學(xué)、分子生物學(xué)、蛋白質(zhì)表達(dá)、純化技術(shù)、基因克隆、微生物學(xué)和免疫學(xué),利用新型高通量技術(shù)開發(fā)重組蛋白、抗體和工程細(xì)胞系并將其商業(yè)化。專注于免疫治療領(lǐng)域,特別是 CAR-T/NK 細(xì)胞技術(shù)。ProMab 還開發(fā)了一種新型的 mRNA 脂質(zhì)納米顆粒(mRNA-LNP)平臺,用于即用型試劑和定制研究服務(wù),以推進(jìn)現(xiàn)有產(chǎn)品并擴(kuò)展到更多的研究領(lǐng)域。

- 注意
-
該頁面的中文產(chǎn)品信息的翻譯,僅供參考。準(zhǔn)確的產(chǎn)品信息請以廠家的英文說明書為準(zhǔn)。下單前,請瀏覽說明書確認(rèn)。
-